kabutan

CHUGAI PHARMA, 19% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed., Dividend Raised by 152 yen

Thu Jan 30, 2025 5:00 pm JST Earnings

4519 CHUGAI PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

CHUGAI PHARMACEUTICAL CO., LTD. <4519> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 30th (17:00). The consolidated net income for the fiscal year ending December 2024 increased 19.0% from the previous period to 387 billion yen. Furthermore, the company did not disclose the performance outlook for the fiscal year ending December 2025.

At the same time, the company decided to implement a year-end dividend of 57 yen for the previous term, which had been previously undecided (making the annual dividend 98 yen), and has decided to significantly increase the dividend this fiscal year to 250 yen, an increase of 152 yen from the previous fiscal year.

In the most recent three-month period, from October to December (4Q), the consolidated net income amounted to 91.5 billion yen, an increase of 0.4% compared to the same period last year. However, the operating profit margin decreased from 44.4% in the same period last year to 40.9%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2022 1,259,726 533,309 531,166 374,429 227.6 78 Feb 2, 2023 IFRS
Dec, 2023 1,111,367 439,174 443,821 325,472 197.8 80 Feb 1, 2024 IFRS
Dec, 2024 1,170,611 542,002 543,034 387,317 235.4 98 Jan 30, 2025 IFRS
YoY +5.3% +23.4% +22.4% +19.0% +19.0%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 Guidance 1,150,000 ー ー ー － － Oct 25, 2024 IFRS
Dec, 2024 Results 1,170,611 542,002 543,034 387,317 235.4 98 Jan 30, 2025 IFRS
Revision Rate +1.8% － － － －

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jan - Jun, 2024 552,860 258,195 258,690 186,262 113.2 41 Jul 25, 2024 IFRS
Jan - Jun, 2025 Guidance ー ー ー ー － 125 Jan 30, 2025 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 1,111,367 439,174 443,821 325,472 197.8 80 Feb 1, 2024 IFRS
Dec, 2024 1,170,611 542,002 543,034 387,317 235.4 98 Jan 30, 2025 IFRS
Dec, 2025 Guidance 1,190,000 ー ー ー － 250 Jan 30, 2025 IFRS
YoY +1.7% － － － －

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 273,812 121,576 122,690 91,206 55.4 44.4 Feb 1, 2024 IFRS
Jan - Mar, 2024 236,949 99,874 99,889 74,401 45.2 42.1 Apr 24, 2024 IFRS
Apr - Jun, 2024 315,911 158,321 158,801 111,861 68.0 50.1 Jul 25, 2024 IFRS
Jul - Sep, 2024 315,678 160,407 158,837 109,496 66.6 50.8 Oct 25, 2024 IFRS
Oct - Dec, 2024 302,073 123,400 125,507 91,559 55.6 40.9 Jan 30, 2025 IFRS
YoY +10.3% +1.5% +2.3% +0.4% +0.4%

Related Articles